Protalix BioTherapeutics ... (PLX)
| Bid | 1.25 |
| Market Cap | 113.84M |
| Revenue (ttm) | 59.76M |
| Net Income (ttm) | 3.91M |
| EPS (ttm) | 0.05 |
| PE Ratio (ttm) | 28.6 |
| Forward PE | 2.29 |
| Analyst | Strong Buy |
| Ask | 1.57 |
| Volume | 677,950 |
| Avg. Volume (20D) | 930,446 |
| Open | 1.48 |
| Previous Close | 1.49 |
| Day's Range | 1.43 - 1.49 |
| 52-Week Range | 0.82 - 3.10 |
| Beta | -0.22 |
Analyst Forecast
According to 0 analyst ratings, the average rating for PLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (NYSE:PLX ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Mike Moyer – Investor Relations Dror Bashan – President and Chief Executive Offi...
1 month ago · proactiveinvestors.com
Protalix eyes Phase II gout trial later this year following solid Q1 revenue growthProtalix Biotherapeutics Inc (NYSE-A:PLX) said it is on track to launch a Phase II clinical trial of its experimental gout treatment PRX-115 later this year, as the company builds on momentum from pos...
2 months ago · proactiveinvestors.com
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMIProtalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the company's unique approach to drug manufacturing using plant cells instead of mammalian cells. He explai...
3 months ago · proactiveinvestors.com
Protalix Biotherapeutics gains momentum: analysts see long-term upsideProtalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio, to partner Chiesi Rare Disease. The company's i...
3 months ago · proactiveinvestors.com
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidateProtalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships, and provided updates on its clinical pipeline, ...
3 months ago · seekingalpha.com
Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call TranscriptProtalix BioTherapeutics, Inc. (NYSE:PLX ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and...